Moreover, we show that c-Abl is a relevant player in AD pathology and that its absence is beneficial for AD, strengthening the use of c-Abl inhibitors as potential disease-modifying drugs for this neurodegenerative disorder and validating neurotinib as a suitable preclinical development candidate for the treatment of AD. Here, ABL1 is linked to Alzheimer disease.